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Abstract
Introduction Improving technologies for the detection and
purification of bone marrow (BM) micrometastatic cells in breast
cancer patients should lead to earlier prognosis of the risk of
relapse and should make it possible to design more appropriate
therapies. The technique used has to overcome the challenges
resulting from the small number of target cells (one per million
hematopoietic cells) and the heterogeneous expression of
micrometastatic cell markers. In the present study, we have
assessed the clinical relevance of current methods aimed at
detecting rare disseminated carcinoma cells.
Methods BM aspirates from 32 carcinoma patients were
screened for the presence of micrometastatic cells positive for
epithelial cell adhesion molecule and positive for cytokeratins,
using optimized immunodetection methods. A comparison with
data obtained for 46 control BM aspirates and a correlation with
the clinical status of patients were performed.
Results We developed a sensitive and efficient
immunomagnetic protocol for the enrichment of BM
micrometastases. This method was used to divide 32 breast
carcinoma patients into three categories according to their
epithelial cell adhesion molecule status. These categories were
highly correlated with the recently revised American Joint
Committee on Cancer staging system for breast cancer,
demonstrating the clinical relevance of this simple and reliable
immunomagnetic technique. We also evaluated
immunocytochemical detection of cytokeratin-positive cells and
cytomorphological parameters. Immunocytochemistry-based
methods for the detection of BM micrometastases did not
provide any information about the clinical status of patients, but
helped to refine the immunomagnetic data by confirming the
presence of micrometastases in some cases. We also tested a
new density gradient centrifugation system, able to enrich the
tumor fraction of BM specimens by twofold to threefold as
compared with standard Ficoll methods.
Conclusion These improved methods for the detection of
micrometastatic cells in patient BM should help clinicians to
predict the clinical status of breast cancer patients at the time of
surgery or treatment.
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Introduction
The most recent estimate of the 10-year relative survival
rate for breast cancer patients is 78% [1]. At the time of
surgery, the clinical prediction of relapse is still based on
the determination of prognostic parameters in the primary
tumor or locoregional lymph nodes. However, histopatho-
logical evaluation often fails to predict the risk of relapse.
Hematogeneous dissemination of occult isolated tumor
cells, so-called 'micrometastases', appears to be the lead-
ing cause of overt metastasis development. The prognostic
value of finding micrometastatic cells in bone marrow (BM)
aspirates of carcinoma patients has been demonstrated
[2,3]. The accurate detection of these cells may therefore
provide additional information for early diagnosis, and may
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help clinicians to select patients for adjuvant therapy and to
monitor patients during follow-up. The purification of
micrometastatic cells should improve the characterization
of the metastatic process, and should facilitate the devel-
opment of new tools and approaches to target the 'minimal
residual disease'.
The methods currently used to evaluate the spreading of
micrometastases are immunocytochemistry (IC) [4,5], RT-
PCR [6,7], flow cytometry [8,9], fluorescence in situ
hybridization [10,11], and immunomagnetic (IM) bead
enrichment [12-15]. Most of these methods rely on the
expression of epithelial markers on the membrane or the
cytoskeleton of carcinoma cells collected from blood or BM
after density gradient centrifugation (Ficoll) of the mononu-
clear cell (MNC) fraction. As disseminated tumor cells are
rare in the BM of breast cancer patients (one to 10 per mil-
lion MNCs), these techniques have to be particularly sensi-
tive and specific to the large spectrum of genes expressed
in BM cells. IM bead enrichment techniques are therefore
considered an essential step in carcinoma cell detection
and purification. We further assessed the power and limita-
tions of this technique. We optimized the IM method for the
detection and purification of tumor cells disseminated in
the BM of breast cancer patients [16]. However, this
method also purified a small but significant number of BM
cells that contaminated the tumor fraction.
In the present study, we first evaluated the clinical rele-
vance of the optimized IM technique, using control BM
specimens and BM aspirates from breast cancer patients
with 'localized disease' or 'advanced disease'. Analysis of
patients' clinical records revealed a correlation between
cancer stage and IM data. Second, we compared the IM
method with the IC method for the detection of BM
micrometastases, and introduced a more efficient Ficoll
procedure into the standard IC protocol. For both tech-
niques, we assessed the contamination of the final fraction
with BM cells and the heterogeneity of the pattern of epi-
thelial cell adhesion molecule (EpCAM) and cytokeratin
(CK) marker expression.
Materials and methods
Patients
After obtaining written informed consent, BM aspirates
were collected from breast cancer patients at the Medical
Division of the Institut Curie. Samples were collected
before starting chemotherapy. Samples were collected
under general anesthesia for 10 patients undergoing pri-
mary tumor surgery and were collected under local
anesthesia for 22 patients with advanced stages of dis-
ease. The mean age of the patients was 50 ± 8 years. Data
were collected blindly. Patient characteristics were pro-
spectively recorded on the Institut Curie medical files. Med-
ical records included the patient's hormonal (estrogen and
progesterone) receptor and Her2 status, histology, grading
and staging of tumors.
BM cells from 46 control patients undergoing hip surgery
were sampled in the Orthopedic Department of Hôpital
Cochin (Paris, France). The mean age of the patients was
62 ± 14 years, and the medical records for each patient
were checked to ensure that they never had previous
carcinoma.
BM processing
Needle aspirates from the upper iliac crest of breast cancer
patients were collected in EDTA K3 Vacutainer tubes (Bec-
ton Dickinson, Franklin Lakes, NJ, USA). Sample volumes
ranged from 2 to 15 ml (mean, 5 ± 4 ml), yielding 138 ± 90
million nucleated cells, which is a mean concentration of 28
million nucleated cells per milliliter. Control BM samples
were collected in sodium citrate Vacutainer tubes. Sample
volumes ranged from 4 to 22 ml (mean, 14 ± 4 ml), yielding
656 ± 447 million nucleated cells, which is a mean concen-
tration of 47 million nucleated cells per milliliter.
BM aspirates were processed immediately or kept at 4°C
for no longer than overnight. After washing in a 10-fold vol-
ume of Hank's balanced salt solution (HBSS), BM samples
were resuspended in HBSS and layered over a Ficoll solu-
tion (HistoPaque-1077; Sigma Diagnostic, St Louis, MO,
USA) in 10 ml LeucoSep tubes (VWR International, Darm-
stadt, Germany), before being centrifuged at 400 × g for
20 min. The resulting gradient density interface was col-
lected and washed in 0.1% BSA in PBS. The OncoQuick
(Greiner Bio-One, Frickenhausen, Germany) gradient den-
sity centrifugation system was tested on BM from several
control patients and was compared with HistoPaque.
For IC experiments, Ficoll-purified cells were resuspended
in 0.1% BSA in PBS at 1 × 106 cells/ml, and were cyt-
ospinned on polylysine-coated slides at 350 × g for 2 min
(Universal 16 Cytocentrifuge; Hettich, Kirchlengern, Ger-
many). After overnight air drying, slides were either proc-
essed immediately for immunochemistry or fixed for 5 min
in 4% formaldehyde and 0.2% sucrose in PBS, before
being stored at -20°C for up to 6 months.
For IM experiments that did not include a Ficoll step, clots
and clumps were first removed by pipetting up and down.
An aliquot containing 50 million nucleated cells was
washed in a 10-fold volume of HBSS. After centrifugation
at 570 × g for 15 min, the pellet was resuspended in 2 ml
of 1% BSA in PBS at 4°C, and was kept on ice until
processing.
Cell lines
MCF7 and T47D cell lines originate from human breast car-
cinoma pleural effusions (ATCC, Manassas, VA, USA).Available online http://breast-cancer-research.com/content/6/5/R556
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Cells were cultured under appropriate conditions and were
shown to be mycoplasma-free.
For spiking assays, cell lines were first labeled for 45 min at
37°C with a vital dye probe (5-chloromethylfluorescein dia-
cetate; Molecular Probes, Eugene, OR, USA) before being
added to BM samples. This bright-green, long-lasting, fluo-
rescent dye can detect as few as 10 live cells among 50
million nucleated BM cells.
Antibodies
The MOC31 monoclonal antibody (kindly given by Prof. O.
Fodstad, The Norwegian Radium Hospital, Oslo, Norway)
is directed against an extracellular epitope of the EpCAM,
and was used at a final concentration of 1 µg/ml. A45-B/
B3 (Chromavision Medical Systems Inc., San Juan Capist-
rano, CA, USA) recognizes a common epitope of the epi-
thelial CK8, CK18 and CK19. Immunolabeling with A45-B/
B3 (1 µg/ml final concentration) is possible after fixing cells
for 5 min in 4% formaldehyde and 0.2% sucrose in PBS.
The anti-human leukocyte common antigen CD45 (4 µg/ml
final concentration), murine IgG1 (2 µg/ml final concentra-
tion), and rabbit anti-mouse (175 µg/ml final concentration)
antibodies, as well as the alkaline phosphatase-anti-alkaline
phosphatase (1 µg/ml final concentration), were purchased
from Dako (Glostrup, Dennmark).
Immunocytochemistry
One million cells per cytospot were immunolabeled at room
temperature with the A45-B/B3 pan-CK antibody, as previ-
ously described [17]. Briefly, cells were fixed for 5 min in
4% formaldehyde and 0.2% sucrose in PBS, were blocked
for 20 min in 10% human serum albumin in Tris-buffered
saline (TBS), and were incubated for 45 min with 1 µg/ml
A45-B/B3 or 2 µg/ml murine IgG1 antibodies in TBS, and
for 15 min with 175 µg/ml rabbit anti-mouse antibody in
TBS. The immune complex was revealed by the alkaline
phosphatase-anti-alkaline  phosphatase/Fuchsin proce-
dure, as described previously [18]. The whole immunolabe-
ling protocol was performed using a Cadenza automated
apparatus (Shandon, San Marcos, CA, USA), and included
5-min washing steps between each incubation. Cytospots
were then counterstained for 2–3 min in a 1/3 dilution of
Mayer's hematoxylin solution (Sigma, St Louis, MO, USA).
After rinsing in tap water for 5 min, slides were mounted
with Faramount mounting medium (Dako) and were
screened using an ACIS automated digital microscope
(Chromavision).
For each patient, three cytospots (i.e. 3 × 106 cells) were
labeled with A45-B/B3, and three other cytospots were
used as negative controls. A positive control slide bearing
the MCF7 breast carcinoma cell line was included in each
experiment. Images of immunoreactive cells were recorded
with the ACIS software (Chromavision) and were reviewed
by a pathologist. Slides were manually analyzed by an inde-
pendent pathologist in a blind manner, in order to check the
morphology of labeled cells.
IM enrichment
M450 magnetic beads (Dynal, Oslo, Norway) coated with
sheep anti-mouse IgG were conjugated to the MOC31
(anti-EpCAM) monoclonal antibody. After washing in the
presence of a magnet, beads were coated with 2 µg anti-
body per milligram of beads, for at least 2 hours at 4°C in
500 µl of 1% BSA in PBS (bead buffer). After washing to
remove excess antibody, the bead suspension (4 × 108
beads/ml) was ready to use and was stored in bead buffer
at 4°C for up to 3 months.
The standard IM protocol was modified as follows [16]. For
each experiment, 50 million nucleated BM cells per tube
were subjected to IM enrichment. The reaction was per-
formed with 10 µl bead suspension, in bead buffer at 4°C
for 30 min under rotation in a 2 ml total volume. After wash-
ing twice in 5 ml ice-cold bead buffer, 50 µl RosetteSep
antibody cocktail (StemCell Technologies, Vancouver,
Canada) was added and incubated for an additional 20 min
at 4°C. These bispecific antibody complexes recognize
CD45-positive (lymphoid cells) and CD66b-positive (gran-
ulocytes) cells, and recognize glycophorin A on erythro-
cytes. These unwanted cells were thus cross-linked and
eradicated during a third washing step. The resulting IM
pellet was then collected in a 50 µl total volume and the
whole fraction was analyzed on glass slides under a light
microscope. Cells with visible nuclei or membranes, meas-
uring more than 12 µm, and rosetted with at least five
beads, were considered positive.
Immunofluorescence
Immunopurified cells were left overnight on polylysine-
coated slides. After fixing for 5 min in 4% formaldehyde and
0.2% sucrose in PBS, and then washing in PBS, cells were
incubated simultaneously with primary and secondary anti-
bodies for 1 hour at room temperature. The Alexa-Fluor 488
goat anti-mouse IgG (Molecular Probes) was used as sec-
ondary antibody (2 µg/ml final concentration), and control
experiments were performed in the absence of primary anti-
body. After mounting with Dako fluorescent mounting
medium, slides were observed by fluorescence micros-
copy. Magnetic beads appeared fluorescent due to the
reaction of their MOC31 monoclonal antibody coat with the
secondary anti-mouse antibody.
Statistics
Differences between the numbers of EpCAM-positive cells
in the different patient populations were analyzed using the
Wilcoxon tests for quantitative and nonparametic variables.
Correlations between the IM groups and stages of disease,
or the IC groups, were analyzed by chi-square tests for cat-Breast Cancer Research    Vol 6 No 5    Choesmel et al.
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egorical variables and by the Mann–Whitney U test for
comparison of two unpaired groups. The Kruskal–Wallis
one-way test was used for multiple comparisons. Statistical
analyses were performed using StatView Software 5.0
(SAS Institute Inc., Cary, NC, USA). Differences were con-
sidered significant if P < 0.05.
Results
IM detection of BM micrometastases and clinical staging 
of breast cancer
IM bead purification techniques have improved the detec-
tion of micrometastases. As micrometastatic cells are
extremely rare, none can be lost during the detection proc-
ess. We thus optimized the standard IM technique based
on EpCAM antigen recognition. This optimized assay can
process an entire crude BM specimen in less than 1 hour
and results are analyzed on just one slide. This highly repro-
ducible technique is able to recover as few as 10 tumor
cells among 50 million nucleated BM cells, with a recovery
yield of about 100% and only 0.01% nonspecific cell drain-
ing [16].
We used this technique to seek MOC31-positive cells in
BM aspirates from 32 breast cancer patients in a blind
manner (Table 1). Medical records showed that the
patients analyzed were representative of the overall breast
cancer population; 81% tested positive for estrogen recep-
tors and/or progesterone receptors, 18% tested positive
for Her2/neu, and 17% exhibited lobular invasive carcino-
mas versus ductal invasive carcinomas. The tumor grade
distribution was 19%, 36% and 45% for grade I, grade II
and grade III, respectively.
The recently revised American Joint Committee on Cancer
(AJCC) staging system for breast cancer [19] was used to
divide patients into two groups. The 'localized disease'
group (n = 10) included stage I and stage IIA patients, most
of whom were recruited at the time of initial surgery. These
patients have T1 and T2 tumor sizes, and less than four
positive lymph nodes. The 'advanced disease' group (n =
22) included stage IIIA–C and stage IV patients. Most of
these patients were recruited before starting initial chemo-
therapy. They exhibit inflammatory tumors or T2, T3 and T4
tumor sizes, and in most cases exhibit a number of positive
lymph nodes.
Prognostic significance of the IM detection of EpCAM-
positive cells in BM of breast cancer patients
We have previously reported the limitations of the EpCAM-
based IM technique, due to the ability of some BM cells to
express EpCAM antigens and to contaminate the immu-
nopurified fraction [16]. We therefore used the IM method
to seek EpCAM-positive cells in 46 control BM specimens,
and in the 10 'localized disease' and the 22 'advanced dis-
ease' breast cancer BM aspirates (Fig. 1). A mean of 68 ±
51 MOC31-positive cells were detected in control samples
(group 1), compared with 84 ± 74 in the 'localized disease'
patients (group 2) and 192 ± 100 in the 'advanced dis-
ease' patients (group 3). The nonparametric Wilcoxon sta-
tistic test showed that the differences between group 1
and group 3, and between group 1 and groups 2 + 3 are
significant (P < 0.0001). However, no significant difference
was found between group 1 and group 2 (P = 0.6226) or
between group 2 and group 3 (P = 0.0115).
Based on the median number of MOC31-positive cells (60
cells for group 1, 101 cells for group 2, and 176 cells for
group 3), we divided the patients into three groups on the
basis of a priori defined threshold values. Indeed, all
'advanced disease' patients had more than 50 MOC31-
positive cells per 50 million nucleated BM cells analyzed,
whereas only five of the 56 control and 'localized disease'
patients had more than 150 cells. Figure 2 shows the dis-
tribution of patients within these three groups: 64% of
'advanced disease' patients were in group A, whereas
group B contained patients of each category, and group C
included only control and 'localized disease' patients. This
classification system, based on the number of cells
detected and the 'clinical category', is highly relevant as
attested by the chi-square statistical test (P < 0.0001).
We subsequently divided the patients in these three IM
groups into two categories based on the 2002 AJCC
tumor staging system (Table 2). Only one patient out of 15
was misclassified in group A, which is equivalent to only
7% nonspecific prediction among stage IIIA–C and stage
IV patients. All patients in group C were correctly predicted
to be at stage I or stage IIA. Chi-square analysis revealed a
strong correlation (P = 0.005) between the stage and the
IM group, and the Kruskal–Wallis nonparametric test
revealed a strong correlation between the stage and the
mean cell number (P = 0.0049). These data demonstrate
the clinical relevance of this optimized IM method, based on
a quantification of EpCAM-positive cells trapped in patient
BM.
Improvement in the density gradient centrifugation 
system for tumor cell enrichment from BM aspirates
We compared a new density gradient centrifugation proto-
col (OncoQuick) with the standard method usually referred
to as Ficoll (HistoPaque). OncoQuick was developed for
blood cell separation and presents the advantage of remov-
ing leukocytes from the collected MNC fraction. To assess
the OncoQuick protocol for BM sample enrichment, we
carried out a model experiment where breast cancer meta-
static cell lines (MCF7, T47D, BC-H1) were labeled with
the 5-chloromethylfluorescein diacetate vital fluorescent
dye, and were mixed with control BM before density gradi-
ent centrifugation processing.Available online http://breast-cancer-research.com/content/6/5/R556
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The amounts of BM and tumor cells recovered were then
determined (Table 3). The OncoQuick and HistoPaque
techniques decreased the number of nucleated BM cells in
the enriched cell fraction by between 9-fold and 14.5-fold
and by between 1.5-fold and 2.5-fold, respectively. Indeed,
10% and 51% of BM cells remained in the purified fraction
using the two techniques, respectively, when 100 million
Table 1
Clinical parameters and staging for 32 breast cancer patients, along with bone marrow immunomagnetic selection data
IM EpCAM-
positive cells
Patients Hormonal
receptor-
positivea
Her2/neu
positivea
Histology Tumor
grade
Tumor  size 2002 AJCC
nodes pN
2002 AJCC
stage
Patient 'disease'
group
103 PM549 1 0 DI II NA 3 IV 'Advanced'
179 PM551 1 0 DI III T3 2 IIIA 'Advanced'
214 PM552 0 0 DI III T4 2 IIIB 'Advanced'
42 PM557 1 0 DI II T1 0 I 'Localized'
7P M 5 6 6 1 0 D I I T 1 0 I ' L o c a l i z e d '
17 PM567 1 0 DI II T1 1 IIA 'Localized'
7 P M 5 6 8 10D I I I T 2 1I I A ' L o c a l i z e d '
180 PM572 1 0 DI III T2 2 IIIA 'Advanced'
101 PM596 1 0 DI I T1 0 I 'Localized'
37 PM597 1 1 LI II T1 0 I 'Localized'
278 PM598 1 1 DI II T4 2 IIIB 'Advanced'
255 PM601 0 0 DI III NA 0 IV 'Advanced'
358 PM602 1 1 DI III T4 NA IIIB 'Advanced'
142 PM603 1 1 DI III T4 2 IIIB 'Advanced'
146 PM608 1 0 DI I T1 0 I 'Localized'
229 PM609 0 0 DI III T2 0 IIA 'Localized'
162 PM612 1 0 DI II T3 2 IIIA 'Advanced'
143 PM613 1 0 DI I T1 0 I 'Localized'
115 PM615 1 0 DI II T2 0 IIA 'Localized'
215 PM618 1 0 LI III NA 3 IV 'Advanced'
140 PM620 1 0 DI III T3 3 IIIC 'Advanced'
67 PM631 1 0 LI II T3 3 IIIC 'Advanced'
172 PM632 0 0 DI III NA 3 IV 'Advanced'
345 PM634 1 1 DI II T3 2 IIIA 'Advanced'
87 PM635 1 0 LI NA T4 2 IIIB 'Advanced'
79 PM642 1 0 DI I T4 2 IIIB 'Advanced'
162 PM643 0 0 DI III T4 0 IIIB 'Advanced'
105 PM644 0 1 DI III T3 3 IIIC 'Advanced'
223 PM649 1 0 DI III T2 2 IIIA 'Advanced'
88 PM655 1 0 DI III T2 2 IIIA 'Advanced'
216 PM656 1 0 LI II T4 1 IIIB 'Advanced'
458 PM658 1 0 LI I T2 3 IIIC 'Advanced'
AJCC, American Joint Committee on Cancer; DI, ductal invasive; EpCAM, Epithelial Cell Adhesion Molecular; IM, immunomagnetic; LI, lobular 
invasive; NA, not available; pN, pathologic lymph node status a1, positive; 0, negative.Breast Cancer Research    Vol 6 No 5    Choesmel et al.
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cells were added. As a result, fivefold fewer cytospots have
to be screened with the standard IC procedure to detect
micrometastases in BM processed with the OncoQuick
protocol.
When 200 T47D cells were mixed with 100 million nucle-
ated BM cells, the mean recovery rates were 41% for
OncoQuick and 34% for HistoPaque. These data are in
agreement with a mean recovery rate of 42% obtained with
both methods for tumor cell enrichment from blood [20].
Although enrichment factors are 10-fold lower in BM than
in blood, the OncoQuick density gradient centrifugation
protocol provides real improvements compared with stand-
Figure 1
Prognostic significance of the immunomagnetic (IM) detection of bone marrow (BM) micrometastases in patients Prognostic significance of the immunomagnetic (IM) detection of bone marrow (BM) micrometastases in patients. The number of MOC31-positive 
cells detected was compared in 46 control patients (group1), and in 10 patients with 'localized' breast cancer (group 2) and 22 patients with 
'advanced' breast cancer (group 3). Data are expressed as the number of MOC31-positive cells found in 50 million crude nucleated BM cells for 
each patient. The median and mean number of cells ± standard deviation of the mean are presented for each patient group.Available online http://breast-cancer-research.com/content/6/5/R556
R562
Figure 2
Classification of patients according to immunomagnetic detection of MOC31-positive cells in bone marrow (BM) specimens Classification of patients according to immunomagnetic detection of MOC31-positive cells in bone marrow (BM) specimens. BM samples from con-
trol patients (white), and from patients with 'localized' breast cancer (gray) and patients with 'advanced' breast cancer (black) were subjected to the 
immunomagnetic technique for the detection of MOC31-positive cells. These patients were then divided into three groups on the basis of the 
number of cells trapped: group A includes patients with more than 150 cells, group B includes those with 50–150 trapped cells, and group C 
includes those with less than 50 cells trapped among 50 million nucleated BM cells.
Table 2
Correlation between breast cancer patient staging and number of EpCAM-positive cells trapped in bone marrow aspirates
2002 AJCC
stages
Patient classification based on IM EpCAM-positive cell numbers
Group A (cells ≥ 150) Group B (50 < cells 
< 150)
Group C (cells < 50) Total patients IM-positive cells
(mean ± SD)
IM-positive cells
(median)
Stages I and IIA 1 4 5 10 84 ± 74 72
Stages IIIA–C 
and IV
14 8 0 22 192 ± 100 176
Total patients 15 12 5 32
IM-positive cells
(mean ± SD)
243 ± 85 110 ± 27 22 ± 17
IM-positive cells
(median)
216 104 17
AJCC, American Joint Committee on Cancer; EpCAM, Epithelial Cell Adhesion Molecule; IM, immunomagnetic; SD, standard deviation of the 
mean.Breast Cancer Research    Vol 6 No 5    Choesmel et al.
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ard Ficoll; first, by increasing the tumor cell density in BM
samples and, second, by reducing the number of slides that
need to be analyzed to achieve a more representative
result.
Relevance of IC detection of CK-positive cells in BM of 
breast cancer patients
Micrometastases were detected by IC and by IM in parallel
using BM aspirates from breast cancer patients. Ten out of
the 32 (31%) BM samples examined were positive for CK-
expressing cells, in agreement with previous studies [2,3].
The frequency of CK-positive cells was between 1 and 11
cells per 3 million BM MNC screened (Fig. 3a). One patient
(PM634), who was stage IIIA at the time of diagnosis,
exhibited a tremendous amount of CK-positive cells (Fig.
3b). This situation was predictive of short-term bone metas-
tasis development followed by death. The median number
of CK-positive cells was 3.5, which is about one cell per
million BM MNC screened.
Besides the difficulty in quantifying micrometastases with
this technique, pathologists reported some nonspecific
labeling of plasmocytes, megakaryocytes, and osteoclasts
present in BM. We therefore used criteria adapted from
Borgen and colleagues [21] and based on the European
ISHAGE (International Society of Hematotherapy and Graft
Engineering) Working Group standardization of tumor cell
detection to classify patients: 12% of patients harbored
CK-positive cells with typical tumor cell morphologies
(class A), 19% of patients harbored CK-positive cells with
no convincing tumor or hematopoietic cell characteristics
(class B), 22% of patients have hematopoietic or squa-
mous skin epithelial CK-reactive (i.e. false-positive) cells
(class C), and 47% of patients had purely CK-negative
cells (class D). This distribution is in agreement with those
reported in larger population trials [17,21].
No correlation was found between the disease progression
according to the 2002 AJCC tumor staging system with
either CK-positive patients (chi-square test, P = 0.0804) or
the mean number of CK-positive cells (Kruskal–Wallis non-
parametric test, P = 0.3238).
Correlation between the IC and IM methods for the 
detection of micrometastases in BM of breast cancer 
patients
To compare these two immunodetection techniques fur-
ther, we divided the 32 breast cancer patients into three IM
groups and four IC classes, as defined earlier (Table 4).
Importantly, none of the IM-negative patients (group C)
were IC-positive (classes A and B), meaning that our quan-
titative IM enrichment method detects every IC-positive
patient. However, only 40% (6/15) of the IM-positive
patients (group A) were IC-positive. Four of the 12 (33%)
patients in the IM group B were IC-positive, providing addi-
tional proof that they were micrometastases-positive. A
combination of the IC technique and the IM enrichment
method may thus increase the number of patients diag-
nosed as micrometastases-positive. However, no direct
correlation could be established between the two tech-
niques regarding the patients or the mean cell numbers, as
assessed with the chi-square test (P = 0.2427) and the
Kruskal–Wallis test (P = 0.5274), respectively.
This led us to address the significance of detecting
EpCAM-positive versus CK-positive carcinoma cells in BM
samples. A thorough analysis of the IC and the IM data
demonstrated that the mean numbers of CK-positive and
EpCAM-positive cells were 1.1 and 3.2 cells per million BM
cells, respectively. This threefold difference may be
explained by the fact that the IC technique screens only 6%
of the BM aspirate and typically detects 0–3 cells/slide.
Tumor cell losses during the indispensable Ficoll step per-
formed before IC may also account for this discrepancy
(32% of cells remaining).
Another explanation could be the heterogeneity of expres-
sion of markers such as CK and EpCAM in carcinoma cells.
As exemplified by immunofluorescence experiments (Fig.
4a), EpCAM-positive BM carcinoma cells may or may not
Table 3
Comparison of density gradient centrifugation systems for the enrichment of disseminated tumor cells in bone marrow (BM)
After Ficoll Gradient System
HistoPaque OncoQuick
Tumor cells recovered (%) 34 ± 2 41 ± 8
BM cells remaining (%) 51 ± 5 10 ± 1
BM mononuclear cell enrichment factor 1.5–2.5 9–14.5
Number of slides 51 10Available online http://breast-cancer-research.com/content/6/5/R556
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Figure 3
Immunocytochemistry targeting cytokeratins (CKs) in bone marrow (BM) aspirates from breast cancer patients Immunocytochemistry targeting cytokeratins (CKs) in bone marrow (BM) aspirates from breast cancer patients. (a) Distribution of CK-positive cells 
for 32 patients. (b) CK-positive cells labeled (purple) by immunocytochemistry performed on BM mononuclear cell cytospots of one breast cancer 
patient with 'advanced disease' (PM634).Breast Cancer Research    Vol 6 No 5    Choesmel et al.
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express CK, reinforcing the idea that two different pools of
carcinoma cells may be detected by the IM and the IC
techniques. Moreover, anti-CK immunohistochemistry per-
formed on primary tumor specimens from patients demon-
strated the large heterogeneity in CK expression on
carcinoma cells (data not shown). Finally, differences in
nonspecific BM cell types and numbers, labeled with anti-
EpCAM and anti-CK antibodies, may introduce such a dis-
crepancy. Indeed, some hematopoietic cells may express
EpCAM molecules and thus be copurified with tumor cells
in BM specimens, as documented both here (Fig. 4b) and
elsewhere [16].
Discussion
We are still unable to predict accurately which patient will
experience breast cancer progression after primary ther-
apy. Improved methods for detecting and characterizing
tumor cells deposited in various compartments of the body
– primarily the lymph nodes, blood and BM – may provide
a better estimate of the individual risk of relapse and may
make it possible to design more effective therapies. There
is growing evidence that there is no correlation between
the presence of micrometastases in the lymph nodes, BM
and blood, and that these three tissues may have distinct
biological and clinical implications [22]. Peripheral blood
should be an ideal source for micrometastatic cell detec-
tion. However, several studies failed to find any clinical rel-
evance of the detection of these cells in blood or sentinel
lymph nodes [17,23,24]. Over the past 5 years, large pro-
spective studies have been conducted on primary breast
carcinoma patients. All of them describe a significant cor-
relation between the presence of immunostained tumor
cells in BM and an unfavorable clinical outcome [3,22,25-
29]. Nevertheless, the reported incidence of BM micromet-
astatic cell detection fluctuates considerably due to varia-
tions in patient series, stage distribution, treatment,
expression of the target antigen, sensitivity and specificity
of the antibody used, and the procedures. Consensus
guidelines have therefore been established by the ISHAGE
European study group to standardize analyses.
With a standardized IC protocol, we detected CK-positive
cells in the BM of 10/32 (31%) breast cancer patients;
seven of these patients (70%) had less than four positive
cells and two patients (20%) had 10 or 11 positive cells
per 3 × 106 BM MNC analyzed. These data are in agree-
ment with the 29% (n  = 62) of CK-positive patients
described in a recent report, with 80% and 20% of patients
having, respectively, 1–3 CK-positive cells and 6–10 CK-
positive cells per 2 × 106 BM MNC analyzed [30]. Among
the breast carcinoma patients positive for epithelial cells in
BM, the average number of tumor cells retrieved after IC
was approximately 1–3 cells per 1 × 106 BM MNC. Usually,
3 × 106 MNC are screened out of the 5–20 × 107 nucle-
ated BM cells in the whole BM aspirate (i.e. only 1/20–1/
70 of the biological sample). In such conditions, a very
reproducible and calibrated technique is required.
Although the method has been standardized to some
extent, we and other workers have observed considerable
variations [21]. We think that it would be best to screen
larger amounts of slides per patient, or to improve the
enrichment procedure when using this assay. We have pre-
viously demonstrated that the tumor cell recovery rate after
density gradient centrifugation (Ficoll) is only 34% [16].
Heterogeneity in tumor cell buoyancy and the formation of
cell clusters may account for this phenomenon. To circum-
vent this problem, we have tested a novel density centrifu-
gation system (OncoQuick) that was initially developed to
enrich carcinoma cells from peripheral blood [20]. A slight
increase in the mean tumor cell recovery rate was observed
(41% compared with 39% for blood [31]). A 3.6-fold to
9.3-fold increase in enrichment factor was obtained with
OncoQuick as compared with standard Ficoll. The Onco-
Quick procedure thus considerably reduces the number of
slides that need to be screened to achieve more quantita-
tive results with IC. However, if the decision is still to rely on
very few positive events, it emphasizes the importance of
carefully characterizing the antibodies applied and the
need to be aware of potential false-positive results.
Table 4
Correlation between immunocytochemistry (IC) cytokeratin (CK) -positive and immunomagnetic (IM) EpCAM-positive breast cancer 
patients
IC morphology IM patient classification
Group A (cells ≥ 150) Group B (50 < cells < 150) Group C (cells < 50) Total patients
Class A (CK-positive, morpho-positive) 3 1 0 10
Class B (CK-positive, morpho-undefined) 3 3 0
Class C (CK-positive, morpho-negative) 4 2 1 22
Class D (CK-negative, morpho-negative) 5 6 4
Total patients 15 12 5 32
CK, cytokeratin; EpCAM, Epithelial Cell Adhesion Molecule; morpho, tumor cell morphology.Available online http://breast-cancer-research.com/content/6/5/R556
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Immunostaining of several breast cancer metastatic cell
lines (MCF7, T47D, BC-H1) and control BM MNC with dif-
ferent antibodies (A45-B/B3, AE1/AE3, KL1) targeting
CKs led us to choose the commonly used A45-B/B3 pan-
CK antibody as a reference. We assume that some variabil-
ity may occur due to slight differences in technical proce-
Figure 4
Immunomagnetic (IM) sorting and immunofluorescence characterization of bone marrow (BM) micrometastatic cells in 'advanced disease' breast  cancer patients Immunomagnetic (IM) sorting and immunofluorescence characterization of bone marrow (BM) micrometastatic cells in 'advanced disease' breast 
cancer patients. BM aspirates were immunopurified using MOC31-conjugated Dynabeads. Following IM sorting, immunofluorescence experiments 
were performed using anti-cytokeratin (a) and anti-CD45 (b) antibodies (green labeling), and were analyzed by light/fluorescence microscopy. Mag-
nification, × 400 (a) and × 200 (b). These data are representative of experiments performed with BM aspirates from several patients.Breast Cancer Research    Vol 6 No 5    Choesmel et al.
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dures (e.g. fixation protocols, antibody concentrations, and
counterstaining solutions). The specificity of A45-B/B3
immunostaining needs to be carefully reappraised accord-
ing to standardized criteria [21]. In our series, we found 6/
32 (19%) patients with A45-B/B3-positive cells, with
unlikely tumor features and showing positive for control
IgG1. This kind of false-positive staining may be the result
of immunoglobulin kappa and lambda subunits reacting
with the alkaline phosphatase-anti-alkaline phosphatase/
fuchsin substrate, as described on mature plasma cells
[32]. In addition, BM cells identified by pathologists as
plasmocytes, megakaryocytes, and osteoclastic cells may
express CKs. IC detected such cells in 7/32 (22%)
patients. These observations are in agreement with the
finding of rare A45-B/B3-positive cells in the BM of 7/20
(35%) control patients [32]. False-positive immunostaining
of hematopoietic cells and CK-expressing BM cells may
thus interfere with the IC detection of micrometastatic cells
in patient BM.
Methods that can detect and further analyze more
micrometastatic cells than the current IC technique are
required. IM enrichment strategies confer an added advan-
tage over IC because they can analyze the whole BM sam-
ple at once, thus increasing the sensitivity of tumor cell
detection. We have developed a simple and highly repro-
ducible IM protocol based on EpCAM antigen recognition
[16]. This method can recover as few as 10 tumor cells
among 5 × 107 nucleated BM cells, with a recovery yield of
about 100% and only 0.01% nonspecific cell draining.
However, the specificity of the method is hampered by the
fact that subpopulations of hematopoietic cells and eryth-
roid progenitors also express EpCAM and copurify with
tumor cells in the sample.
In our series of 32 breast cancer patients with 'localized
disease' and 'advanced disease', we assessed the clinical
value of this IM assay by classifying patients on the basis of
the recently revised AJCC staging system for breast cancer
[19]. This emphasizes that a combination of high sensitivity
and quantitative results is the most important advantage of
IM enrichment, as the number of EpCAM-positive cells
detected provides clinical significance. Previous studies
using IM to detect BM micrometastatic cells in colorectal
cancer patients failed to detect any correlation between the
number of EpCAM-positive cells and the stage of disease
[13].
We also show that IC detection of CK-positive cells for the
same patient population is not correlated to the stage of
disease. IC detection is of better prognostic value when
clinical trials include a large number of patients (at least
100), but it cannot provide individual predictions. However,
we demonstrate here that patient classification according
to IM results may benefit from IC data.
Difficulties in finding correlations between the IM and IC
methods for the detection of micrometastatic cells have
been reported in the literature. Besides the difference in
sensitivity due to different enrichment protocols, we sug-
gest that both methods may detect different tumor cell sub-
populations that differentially express the CK and EpCAM
antigens. Indeed, we showed here and elsewhere [16] that
EpCAM-positive BM cells may or may not express CK. Pre-
vious studies on breast cancer patients have reported that
68% (range, 48–100%) of CK-positive cells are EpCAM-
positive in BM [33], and that only 28% of EpCAM-positive
cells are CK-positive in blood [24]. A recent study per-
formed on breast cancer patients treated with adjuvant
chemotherapy reported that none of the CK-positive cells
detected in BM using IC were EpCAM-positive, and that
only 7.4% of BM specimens harbored CK-positive cells
after EpCAM IM selection [30]. We agree that Ficoll
processing might eliminate cell clusters or aggregates,
leading to the preferential loss of EpCAM-expressing cells.
However, we believe that intrinsic tumor heterogeneity is
the main explanation for the observed variations. Our
assumption is based on the evaluation of A45-B/B3 immu-
nostaining in primary tumor tissues for a set of ductal or lob-
ular invasive carcinoma patients, which demonstrated large
variations in CK expression (data not shown). In accord-
ance, a comparison of breast cancer patient specimens
using immunostaining and quantitative RT-PCR showed
that EpCAM and CK19 mRNA levels vary considerably (>
104-fold and > 103-fold, respectively) in primary tumors,
and that certain tumors cannot contain high or low levels of
both markers simultaneously [34]. The expression level for
EpCAM may vary between colorectal and breast cancer
[35], or within breast cancer primary tumors in a bimodal
(low or high) manner [36].
Additional heterogeneity may be generated by dissemi-
nated cells, which have to acquire invasive properties,
escape immune mechanisms, adaptative and dormancy
capacities before they can reach secondary sites such as
BM. Previous studies have revealed the variable expression
pattern of antigens in micrometastases [37]. The expres-
sion of the EpCAM antigen might be modulated during the
proliferation and dedifferentiation steps that occur during
the progression of cancer. EpCAM may be downregulated
on metastatic tumor cells because loss of cell-cell adhesion
is a prerequisite for tumor cell dissemination [38,39]. The
epithelial–mesenchymal transition occurring in metastatic
processes leads to a transient loss of EpCAM expression
during the migratory and early postmigratory period [40].
The sole in vitro mechanism described that can account for
EpCAM downregulation is a transcriptional effect induced
by tumor necrosis factor alpha and mediated by nuclear
factor kappaB [41].Available online http://breast-cancer-research.com/content/6/5/R556
R568
Modulation of CK expression along with tumor progression
has also been reported [42-44]. Major CK alterations
observed in breast cancer could be reflected by the
reduced or increased expression of individual CK, and by
partial loss of the normal regulation of CK expression [45].
The fact that subsets of disseminated cells can express
EpCAM and CK markers independently, and that carci-
noma cells with low antigen expression may be missed by
both methods, may account for the difficulty in reconciling
IC and IM data.
Conclusion
The present study demonstrates that it is of uppermost
importance to test rigorously the performance of tech-
niques for detecting rare cells such as micrometastases,
before carrying out large-scale clinical studies. Until a 'uni-
versal' and 'fully specific' surface antigen is discovered, a
combination of markers, techniques, and approaches might
help to overcome the limitations of detection procedures.
Therefore, after evaluating the potential and the failure of
the IM and IC methods, we have introduced substantial
optimizations and demonstrated the clinical relevance of
the quantitative IM technique in association with IC. This
more accurate detection of BM micrometastatic cells may
help to classify breast cancer patients and may constitute
key information for the clinician in the administration of adju-
vant therapy.
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